Ninlaro FDA Approval History
FDA Approved: Yes (First approved November 20, 2015)
Brand name: Ninlaro
Generic name: ixazomib
Dosage form: Capsules
Company: Takeda Pharmaceutical Company Limited
Treatment for: Multiple Myeloma
Ninlaro (ixazomib) is an oral proteasome inhibitor indicated for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Development timeline for Ninlaro
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.